A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) profiles of otilimab in healthy Japanese participants.

Timeline

Start

2023-02-08

Primary completion

2023-05-04

Completion

2023-05-04

Outcome

Outcome not reported

Stopped: “This study was cancelled because of the limited efficacy demonstrated in the ContRAst phase III programme as a potential treatment for rheumatoid arthritis. GSK has decided not to progress with regulatory submissions”

Drugs

Indications